Dyadic International (NASDAQ:DYAI – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Dyadic International and […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective lowered by HC Wainwright from $15.00 to $14.00 in a research report sent to investors on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Cardiff Oncology’s Q2 2023 earnings at ($0.26) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price dropped by research analysts at HC Wainwright from $15.00 to $14.00 in a report issued on Tuesday, The Fly reports. Cardiff Oncology Stock Down 3.4 % Shares of Cardiff Oncology stock opened at $1.71 on Tuesday. Cardiff Oncology has a twelve month low of $1.13 […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price target decreased by research analysts at HC Wainwright from $15.00 to $14.00 in a research note issued to investors on Tuesday, The Fly reports. Cardiff Oncology Trading Down 4.3 % NASDAQ CRDF opened at $1.80 on Tuesday. The stock has a market capitalization of $80.42 million, […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 624,300 shares, a decline of 7.3% from the March 15th total of 673,600 shares. Based on an average daily volume of 240,900 shares, the […]